Migliaccio & Rathod LLP is investigating whether the Dupixent side effects may include a higher risk for T-cell lymphoma.

What is Dupixent?

Dupixent (dupilumab) is a medication used to treat certain skin and respiratory conditions. It has been a top-selling drug and effective for treatment. However, recent research has begun to indicate that there may be serious health concerns related to the Dupixent side effects and the risk of T-cell lymphoma.

Dupixent is a prescription injectable medication. It is used to treat various conditions, such as moderate to severe eczema, asthma, and more. Dupixent was first approved in 2017 by the U.S. Food and Drug Administration as a treatment for atopic dermatitis, also known as eczema. Its approved uses have since expanded and it is now used to treat asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, Prurigo nodularis, and chronic obstructive pulmonary disease.

What is the concern with Dupixent Side Effects?

The drug works by blocking a key source of inflammation in the body. It has been effective at reducing symptoms in this way. However, recent research is showing that this may also have dangerous consequences. The process that makes Dupixent effective at treating this inflammation may also interfere with the body’s ability to regulate abnormal cells. This may allow cancer cells to develop.

Shortly after it went on the market, research began to emerge linking Dupixent with T-cell lymphoma. T-cell lymphoma is a type of cancer that affects the immune system. Specifically, Dupixent has been connected with Cutaneous T-cell Lymphoma, which starts on the skin, and Peripheral T-cell Lymphoma, which is found in the lymph nodes.

Several studies have emerged that show the possibility of this connection. Though research is still ongoing to determine what that relationship might be, many feel that Dupixent is not taking sufficient action to warn of the possible risk and that manufacturers Regeneron Pharmaceuticals and Sanofi-Aventis should be doing more.

Who may be affected?

If you take Dupixent, have been taking Dupixent for an extended amount of time, or have developed problematic side effects, we encourage you to reach out. Please complete the contact form on this page, send us an email at [email protected], or give us a call at (202) 470-3520.

The following will ask for your contact information so that we may reach you to talk about potential claims. This information is for our records only and will not be shared. By continuing, you consent to the collection of this information for these limited purposes.

Your name Your phone number Your email State of Residence Age: How long were you on/have you been on Dupixent?
Are you still on Dupixent?
Have you ever had a lymphoma diagnosis?
Have you had a baseline skin biopsy (either a skin biopsy before taking Dupixent or at any other times)?
If you have had a baseline skin biopsy, what were the results of that biopsy? Would you like to join our newsletter to receive notifications about other investigations we're looking into, as well as updates on ongoing cases?
By submitting this form, you consent to receive marketing, updates, and informative SMS messages from Migliaccio & Rathod LLP at the email and/or phone number provided. Consent is not a condition of purchase. Message & data rates may apply. Message frequency varies. Unsubscribe at any time by replying STOP or Reply HELP for help. Privacy Policy

The lawyers at Migliaccio & Rathod LLP have years of experience in class action litigation against large corporations, including in cases involving product defects such as this. More information about our current cases and investigations is available on our blog.